Interesting to see how the ptx200’s progression-free survival data is holding up on the phase 1b Ovarian readout;
AstraZeneca and Merck & Co. have just had a set back:
https://www.biopharmadive.com/news/astrazeneca-merck-lynparza-cediranib-ovarian-cancer/574019/
"Measured by progression-free survival, or the length of time patients live without their tumors getting larger or spreading, the Lynparza-cediranib combination did no better than platinum-based chemotherapy."
- Forums
- ASX - By Stock
- PTX
- Ann: Encouraging data from PTX-200 ovarian cancer trial
Ann: Encouraging data from PTX-200 ovarian cancer trial, page-171
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.82M |
Open | High | Low | Value | Volume |
4.2¢ | 4.3¢ | 4.2¢ | $2.103K | 50.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 72361 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 625714 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 72361 | 0.042 |
3 | 188129 | 0.041 |
12 | 970055 | 0.040 |
3 | 243333 | 0.039 |
9 | 544473 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 625714 | 4 |
0.044 | 120777 | 2 |
0.047 | 86129 | 3 |
0.048 | 62664 | 3 |
0.049 | 39540 | 1 |
Last trade - 12.50pm 07/11/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |